ZEISS is an international leader in the fields of optics and optoelectronics. The more than 24,000 employees of ZEISS generated revenue of about 4.2 billion euros in fiscal year 2012/13. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.
ZEISS is represented in over 40 countries around the globe with more than 40 manufacturing sites, around 50 sales and service locations, and over 20 research and development centers. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).
From routine analysis to new discoveries, Thermo Scientific innovations help professionals do the science they need to do, the way they want to do it. High-end analytical instruments, laboratory equipment, software, services, consumables and reagents help customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.
Customers include universities and other organizations involved in various fields of nanotechnology research and materials science – as well as industrial and medium sized enterprises that use nanotechnology for specific product applications or produce compound semiconductors.
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases thro...
The Company is the global leader in cardiac genetic testing with a family of innovative products designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
Тел./факс: +49 721 981 980 0/+49 721 981 980 email@example.com www.nanoscribe.com
Nanoscribe has established itself in this field as the technological and global market leader with its laser lithographic processes. Our 3D lithography systems are spread throughout Europe, Asia, North America as well as Australia. The performance of the groundbreaking Photonic Professional GT system generation was emphasized in February 2014 by being awarded a Prism Award in San Francisco, the "Oscar of Photonics" in the category "Advanced Manufacturing". Based on the technique of two-photon polymerization, these 3D laser lithography systems offer submicron feature sizes on or below the length scale of the wavelength of light. When common additive manufacturing technologies like stereolithography reach their limits, these 3D printers reveal their full potential providing a 100x higher resolution. Previously unavailable design freedom in microfabrication and structural heights far beyond conventional lithography techniques guarantee outstanding solutions and make them an indispensable tool for scientific as well as industrial customers.
We serve scientific and industrial customers and develop customised solutions and processes for specific industrial applications. Nanoscribe is a member of the European Photonics Industry Consortium EPIC and the Competence Network for Optical Technologies in Baden-Württemberg Photonics BW .
SEC prides itself on observing today's ever-changing needs for its customers by providing the most advanced and efficient technology in order to meet customer's production demands. Additionally, our goal is to provide the best service and attention to detail in order to exceed our customer's needs in a constantly evolving, technological environment.
The company started in France as a manufacturer of movie theater projectors, and soon the CAMECA products evolved into scientific instrumentation. Since pioneering Electron Probe MicroAnalysis (EPMA) in the 1950's and Secondary Ion Mass Spectrometry (SIMS) in the 1960's, CAMECA has remained the undisputed world leader in these techniques while achieving numerous breakthrough innovations in complementary techniques such as Low energy Electron induced X-ray Emission Spectrometry (LEXES), and 3D Atom Probe. CAMECA has evolved from a manufacturer of scientific instrumentation for the international research community to a provider of in-fab and near-fab metrology solutions for the semiconductor manufacturing industry.
Today, CAMECA employs over 300 employees around the world, with locations in the USA, Germany, Japan, Korea, China, and Taiwan, and a wide network of agents, ensuring the best level of support to all users. Our mission is to focus on instrumental development to offer our customers the highest analytical performance in their specialized characterization fields.
CAMECA is headquartered in Gennevilliers near Paris, France. Our plant is a state-of-the-art facility with clean room environment, electron and ion optics simulation, advanced CAD, UHV cleaning... Operating under ISO 9001 certification, CAMECA controls not only the technology, but all aspects in the designing, manufacturing, installing and servicing of its products.
In 2007, CAMECA joined AMETEK, Inc., a leading global provider of electronic instruments and electromechanical devices, as part of the AMETEK Materials Analysis Division.